CureVac NV reports Q3 net profit of €273.2 million and nine-month net profit of €161.6 million

Reuters

11/24

CureVac NV reports Q3 net profit of €273.2 million and nine-month net profit of €161.6 million

CureVac NV reported a net profit of €273.2 million for the third quarter of 2025, down from €338.0 million in the same period of 2024. Net profit for the first nine months of 2025 was €161.6 million, compared to €194.9 million in the prior-year period. The net financial result showed a loss of €2.6 million for the third quarter of 2025, compared to a gain of €2.2 million in the previous year, mainly due to unrealized foreign exchange losses. Basic and diluted earnings per share for the third quarter were €1.21, compared to €1.51 and €1.50 respectively in 2024. For the first nine months, basic earnings per share were €0.72 and diluted earnings per share were €0.71, down from €0.87 and €0.86 in the previous year. Revenues were €54.1 million for the third quarter and €56.3 million for the first nine months of 2025. Business developments included clearance from the German Federal Cartel Office for the planned BioNTech-CureVac transaction and the start of BioNTech's public exchange offer for all outstanding CureVac shares, set to expire on December 3, 2025. CureVac also reaffirmed its expected cash runway into 2028.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CureVac NV published the original content used to generate this news brief via EQS News, a service of EQS Group AG (Ref. ID: corporate_2235000_en), on November 24, 2025, and is solely responsible for the information contained therein.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2585461140"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2585461140\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2585461140?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-24 20:13","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2585461140","market":"fut","top_or_hot":-1,"title":"CureVac NV reports Q3 net profit of €273.2 million and nine-month net profit of €161.6 million","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      CureVac NV reports Q3 net profit of €273.2 million and nine-month net profit of €161.6 million\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        CureVac NV reported a net profit of €273.2 million for the third quarter of 2025, down from €338.0 million in the same period of 2024. Net profit for the first nine months of 2025 was €161.6 million, compared to €194.9 million in the prior-year period. The net financial result showed a loss of €2.6 million for the third quarter of 2025, compared to a gain of €2.2 million in the previous year, mainly due to unrealized foreign exchange losses. Basic and diluted earnings per share for the third quarter were €1.21, compared to €1.51 and €1.50 respectively in 2024. For the first nine months, basic earnings per share were €0.72 and diluted earnings per share were €0.71, down from €0.87 and €0.86 in the previous year. Revenues were €54.1 million for the third quarter and €56.3 million for the first nine months of 2025. Business developments included clearance from the German Federal Cartel Office for the planned BioNTech-CureVac transaction and the start of BioNTech's public exchange offer for all outstanding CureVac shares, set to expire on December 3, 2025. CureVac also reaffirmed its expected cash runway into 2028.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CureVac NV published the original content used to generate this news brief via EQS News, a service of EQS Group AG (Ref. ID: corporate_2235000_en), on November 24, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>CureVac NV reports Q3 net profit of €273.2 million and nine-month net profit of €161.6 million</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCureVac NV reports Q3 net profit of €273.2 million and nine-month net profit of €161.6 million\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-24 20:13</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      CureVac NV reports Q3 net profit of €273.2 million and nine-month net profit of €161.6 million\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        CureVac NV reported a net profit of €273.2 million for the third quarter of 2025, down from €338.0 million in the same period of 2024. Net profit for the first nine months of 2025 was €161.6 million, compared to €194.9 million in the prior-year period. The net financial result showed a loss of €2.6 million for the third quarter of 2025, compared to a gain of €2.2 million in the previous year, mainly due to unrealized foreign exchange losses. Basic and diluted earnings per share for the third quarter were €1.21, compared to €1.51 and €1.50 respectively in 2024. For the first nine months, basic earnings per share were €0.72 and diluted earnings per share were €0.71, down from €0.87 and €0.86 in the previous year. Revenues were €54.1 million for the third quarter and €56.3 million for the first nine months of 2025. Business developments included clearance from the German Federal Cartel Office for the planned BioNTech-CureVac transaction and the start of BioNTech's public exchange offer for all outstanding CureVac shares, set to expire on December 3, 2025. CureVac also reaffirmed its expected cash runway into 2028.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CureVac NV published the original content used to generate this news brief via EQS News, a service of EQS Group AG (Ref. ID: corporate_2235000_en), on November 24, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4548","symbol_name":"巴美列捷福持仓","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251124:nNDL6dTwrC:1","article_id":"2585461140","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2585461140","pubTimestamp":1763986402,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"CureVac NV reported a net profit of 273.2 million for the third quarter of 2025, down from 338.0 million in the same period of 2024. Net profit for the first nine months of 2025 was 161.6 million, compared to 194.9 million in the prior-year period. The net financial result showed a loss of 2.6 million for the third quarter of 2025, compared to a gain of 2.2 million in the previous year, mainly due to unrealized foreign exchange losses. Basic and diluted earnings per share for the third quarter were 1.21, compared to 1.51 and 1.50 respectively in 2024. For the first nine months, basic earnings per share were 0.72 and diluted earnings per share were 0.71, down from 0.87 and 0.86 in the previous year. Revenues were 54.1 million for the third quarter and 56.3 million for the first nine months of 2025. Business developments included clearance from the German Federal Cartel Office for the planned BioNTech-CureVac transaction and the start of BioNTech's public exchange offer for all outstandi","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4548":"巴美列捷福持仓","BK4551":"寇图资本持仓","BK4568":"美国抗疫概念","BNTX":"BioNTech SE","BK4588":"碎股","BK4139":"生物科技","BK4585":"ETF&股票定投概念","BK4535":"淡马锡持仓","CVAC":"CureVac B.V."},"translate_title":"CureVac NV报告第三季度净利润为2.732亿欧元，九个月净利润为1.616亿欧元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CVAC":0.9,"BNTX":0.9},"content_text":"CureVac NV reports Q3 net profit of €273.2 million and nine-month net profit of €161.6 million\n    \n\n        CureVac NV reported a net profit of €273.2 million for the third quarter of 2025, down from €338.0 million in the same period of 2024. Net profit for the first nine months of 2025 was €161.6 million, compared to €194.9 million in the prior-year period. The net financial result showed a loss of €2.6 million for the third quarter of 2025, compared to a gain of €2.2 million in the previous year, mainly due to unrealized foreign exchange losses. Basic and diluted earnings per share for the third quarter were €1.21, compared to €1.51 and €1.50 respectively in 2024. For the first nine months, basic earnings per share were €0.72 and diluted earnings per share were €0.71, down from €0.87 and €0.86 in the previous year. Revenues were €54.1 million for the third quarter and €56.3 million for the first nine months of 2025. Business developments included clearance from the German Federal Cartel Office for the planned BioNTech-CureVac transaction and the start of BioNTech's public exchange offer for all outstanding CureVac shares, set to expire on December 3, 2025. CureVac also reaffirmed its expected cash runway into 2028.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CureVac NV published the original content used to generate this news brief via EQS News, a service of EQS Group AG (Ref. ID: corporate_2235000_en), on November 24, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}